On October 10, 2023, Henglu Biotech's LNTⅡ (Lacto-N-trioseⅡ) received expert approval for its SELF-GRAS scientific evaluation in accordance with FDA GRAS guidelines. At the same time, Henglu Biotech's independently developed HMOs, including 2’-FL (2’-Fucosyllactose), LNT (Lacto-N-tetraose), LNnT (Lacto-N-neotetraose), and LNB (Lacto-N-Biose), have been progressively submitted for safety certification applications to relevant authorities in the United States, European Union, Australia, New Zealand, and domestic regulatory bodies. The successful completion of the SELF GRAS safety certification signifies that Henglu Biotech's HMO products have entered a fully commercialized stage.

In mid-September, Henglu Biotech's lactose-N-trioseⅡ production strain (yeast) received safety certification from the Ministry of Agriculture and Rural Affairs of China. Lactose-N-trioseⅡ is an important member of the human milk oligosaccharides (HMO) family, and research has shown that it plays a significant role in supporting infant health by contributing to immune regulation, inflammation reduction, and NK cell activation. A study by Vanderbilt University demonstrated that among the components of human milk oligosaccharides, lactose-N-triose is the most effective in inhibiting the growth of GBS bacteria, indicating that the intake of lactose-N-triose can reduce the risk of various neonatal diseases such as pneumonia, sepsis, and meningitis. Research from Wageningen University has proved that the intake of lactose-N-triose affects the healthy balance of gut microbiota in the human body.

Lactose-N-triose enhances the adhesion capacity of intestinal epithelial cells and increases the production of succinate and short-chain fatty acids, not only promoting the colonization of beneficial bacteria and quickly improving their abundance but also reducing the abundance of pathogenic bacteria, as well as lowering the incidence of inflammation by interacting with the intestinal epithelial cells of infants and adults. Furthermore, it has been shown that lactose-N-triose can activate NF-κB through the TLR pathway, enhancing the immune regulatory function of NK macrophages. These medical studies confirm that Lacto-N-trioseⅡ not only reduces the incidence of diseases in newborns but also plays an important role in the health of individuals across all age groups.

In September 2023, Henglu Biotech and Shiyao Shengxue Company established a joint venture to build a production center for human milk oligosaccharides (HMOs).

References:

[1] Fang et al., International Journal of Toxicology. 2023. DOI: 10.1177/10915818231203515.

[2] Craft et al., ACS Infectious Diseases. 2018.4(12):1755-1765. DOI: 10.1021/acsinfecdis.8b00234.

[3] Kong et al., Food&Function. 2021. 12(24):12513-12525. DOI: 10.1039/d1fo02563e.

[4] Cheng et al., Journal of Functional Foods. 2019. 59:174-184. DOI: 10.1016/j.jff.2019.05.023.